248 related articles for article (PubMed ID: 31660863)
1. Adherence to anti-osteoporosis medication associated with lower mortality following hip fracture in older adults: a nationwide propensity score-matched cohort study.
Yu SF; Cheng JS; Chen YC; Chen JF; Hsu CY; Lai HM; Ko CH; Chiu WC; Su YJ; Cheng TT
BMC Geriatr; 2019 Oct; 19(1):290. PubMed ID: 31660863
[TBL] [Abstract][Full Text] [Related]
2. Anti-Osteoporosis Medications Associated with Decreased Mortality after Hip Fracture.
Wang PW; Li YZ; Zhuang HF; Yu HM; Cai SQ; Xu H; Chen ZH; Lin JK; Yao XD
Orthop Surg; 2019 Oct; 11(5):777-783. PubMed ID: 31429532
[TBL] [Abstract][Full Text] [Related]
3. Comparative effectiveness of osteoporosis drugs in preventing secondary nonvertebral fractures in Taiwanese women.
Lin TC; Yang CY; Yang YH; Lin SJ
J Clin Endocrinol Metab; 2013 Dec; 98(12):4717-26. PubMed ID: 24081731
[TBL] [Abstract][Full Text] [Related]
4. Alendronate medication possession ratio and the risk of second hip fracture: an 11-year population-based cohort study in Taiwan.
Chen YJ; Kung PT; Chou WY; Tsai WC
Osteoporos Int; 2020 Aug; 31(8):1555-1563. PubMed ID: 32221674
[TBL] [Abstract][Full Text] [Related]
5. Association of Bone Density Monitoring in Routine Clinical Practice With Anti-Osteoporosis Medication Use and Incident Fractures: A Matched Cohort Study.
Leslie WD; Morin SN; Martineau P; Bryanton M; Lix LM
J Bone Miner Res; 2019 Oct; 34(10):1808-1814. PubMed ID: 31211871
[TBL] [Abstract][Full Text] [Related]
6. Drug adherence and treatment duration for denosumab and mortality risk among hip fracture patients.
Tsai YL; Wu CH; Li CC; Shih CA; Chang YF; Hwang JS; Tai TW
Osteoporos Int; 2023 Oct; 34(10):1783-1791. PubMed ID: 37466659
[TBL] [Abstract][Full Text] [Related]
7. Association between teriparatide treatment persistence and adherence, and fracture incidence in Taiwan: analysis using the National Health Insurance Research Database.
Chan DC; Chang CH; Lim LC; Brnabic AJM; Tsauo JY; Burge R; Hsiao FY; Jin L; Gürbüz S; Yang RS
Osteoporos Int; 2016 Sep; 27(9):2855-2865. PubMed ID: 27172935
[TBL] [Abstract][Full Text] [Related]
8. Use of antiosteoporotic drugs and calcium/vitamin D in patients with fragility fractures: impact on re-fracture and mortality risk.
Degli Esposti L; Girardi A; Saragoni S; Sella S; Andretta M; Rossini M; Giannini S;
Endocrine; 2019 May; 64(2):367-377. PubMed ID: 30515678
[TBL] [Abstract][Full Text] [Related]
9. Association of Osteoporosis Medication Use After Hip Fracture With Prevention of Subsequent Nonvertebral Fractures: An Instrumental Variable Analysis.
Desai RJ; Mahesri M; Abdia Y; Barberio J; Tong A; Zhang D; Mavros P; Kim SC; Franklin JM
JAMA Netw Open; 2018 Jul; 1(3):e180826. PubMed ID: 30646034
[TBL] [Abstract][Full Text] [Related]
10. Antiresorptive therapy and risk of mortality and refracture in osteoporosis-related hip fracture: a nationwide study.
Brozek W; Reichardt B; Zwerina J; Dimai HP; Klaushofer K; Zwettler E
Osteoporos Int; 2016 Jan; 27(1):387-96. PubMed ID: 26576544
[TBL] [Abstract][Full Text] [Related]
11. The Impact of Various Anti-Osteoporosis Drugs on All-Cause Mortality After Hip Fractures: A Nationwide Population Study.
Tai TW; Hwang JS; Li CC; Hsu JC; Chang CW; Wu CH
J Bone Miner Res; 2022 Aug; 37(8):1520-1526. PubMed ID: 35689432
[TBL] [Abstract][Full Text] [Related]
12. The association between osteoporosis medications and lowered all-cause mortality after hip or vertebral fracture in older and oldest-old adults: a nationwide population-based study.
Li CC; Hsu JC; Liang FW; Chang YF; Chiu CJ; Wu CH
Aging (Albany NY); 2022 Mar; 14(5):2239-2251. PubMed ID: 35232893
[TBL] [Abstract][Full Text] [Related]
13. Hip and other fragility fracture incidence in real-world teriparatide-treated patients in the United States.
Burge RT; Disch DP; Gelwicks S; Zhang X; Krege JH
Osteoporos Int; 2017 Mar; 28(3):799-809. PubMed ID: 28028555
[TBL] [Abstract][Full Text] [Related]
14. Declining rates of osteoporosis management following fragility fractures in the U.S., 2000 through 2009.
Balasubramanian A; Tosi LL; Lane JM; Dirschl DR; Ho PR; O'Malley CD
J Bone Joint Surg Am; 2014 Apr; 96(7):e52. PubMed ID: 24695929
[TBL] [Abstract][Full Text] [Related]
15. Osteoporosis medication use after hip fracture in U.S. patients between 2002 and 2011.
Solomon DH; Johnston SS; Boytsov NN; McMorrow D; Lane JM; Krohn KD
J Bone Miner Res; 2014 Sep; 29(9):1929-37. PubMed ID: 24535775
[TBL] [Abstract][Full Text] [Related]
16. Incidence of second hip fractures and associated mortality in Taiwan: A nationwide population-based study of 95,484 patients during 2006-2010.
Lee SH; Chen IJ; Li YH; Fan Chiang CY; Chang CH; Hsieh PH
Acta Orthop Traumatol Turc; 2016 Aug; 50(4):437-42. PubMed ID: 27473531
[TBL] [Abstract][Full Text] [Related]
17. Patients' first-year adherence to different anti-osteoporotic therapy after hip fractures.
Kim SJ; Cho YJ; Lee DW
Injury; 2021 Jun; 52(6):1506-1510. PubMed ID: 33223260
[TBL] [Abstract][Full Text] [Related]
18. Medical specialty-related adherence to anti-osteoporotic regimens in fragility hip fracture patients.
Hsu CY; Chiu WC; Chen JF; Chou CL; Su YJ; Yu SF; Cheng TT
J Bone Miner Metab; 2015 Sep; 33(5):577-83. PubMed ID: 25240801
[TBL] [Abstract][Full Text] [Related]
19. Alendronate adherence and its impact on hip-fracture risk in patients with established osteoporosis in Taiwan.
Lin TC; Yang CY; Yang YH; Lin SJ
Clin Pharmacol Ther; 2011 Jul; 90(1):109-16. PubMed ID: 21525868
[TBL] [Abstract][Full Text] [Related]
20. Fractures and mortality in relation to different osteoporosis treatments.
Yun H; Delzell E; Saag KG; Kilgore ML; Morrisey MA; Muntner P; Matthews R; Guo L; Wright N; Smith W; Colón-Emeric C; O'Connor CM; Lyles KW; Curtis JR
Clin Exp Rheumatol; 2015; 33(3):302-9. PubMed ID: 25068266
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
